Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.

Qingwu Wu,Yana Zhang,Weifeng Kong,Xinyue Wang,Lianxiong Yuan,Rui Zheng,Huijun Qiu,Xuekun Huang,Qintai Yang

International archives of allergy and immunology（2022）

引用 24|浏览23

暂无评分

摘要

This is the first NMA that compared different biologics in patients with CRSwNP. Based on the efficacy (NPS) and safety (AEs), dupilumab is the best choice and omalizumab is the second best option for CRSwNP. Although mepolizumab ranked second in efficacy, it had the highest risk of AEs.

查看译文

关键词

Dupilumab,Mepolizumab,Nasal polyps,Network meta-analysis,Omalizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要